Open AccessSwitching to a Protease Inhibitor-Containing, Nucleoside-Sparing Regimen (Lopinavir/Ritonavir Plus Efavirenz) Increases Limb Fat But Raises Serum Lipid Levels
Author(s) -
Pablo Tebas,
Jiameng Zhang,
Kevin E. Yarasheski,
Scott Evans,
Margaret A. Fischl,
Abby Shevitz,
Judith Feinberg,
Ann C. Collier,
Cecilia Shikuma,
Barbara Brizz,
Fred R. Sattler
Publication year - 2007
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0b013e318042e204
Subject(s) - lopinavir , ritonavir , efavirenz , lopinavir/ritonavir , protease inhibitor (pharmacology) , regimen , medicine , virology , nucleoside reverse transcriptase inhibitor , pharmacology , human immunodeficiency virus (hiv) , viral load , antiretroviral therapy
Subcutaneous limb fat loss continues to be one the most troubling side effects of long-term antiretroviral regimens. Nucleoside analogues and protease inhibitors (PIs) have been linked to the development of this complication.